DIAN Forms Pharma Consortium, Submits Treatment Trial Grant
In their quest to offer treatment trials to families with autosomal-dominant AD, the scientists driving the DIAN have cleared the next hurdles...
120 RESULTS
Sort By:
In their quest to offer treatment trials to families with autosomal-dominant AD, the scientists driving the DIAN have cleared the next hurdles...
Over the past five years, the field at large has reached strong consensus that clinical trials should treat people earlier...
All those who follow the Alzheimer's Prevention Initiative may want to check out a recent New York Times article...
A collective push is for therapeutic trials to start within the next two years in three different types of patients...
Recent findings have strengthened the scientific underpinning of the Alzheimer’s Prevention Initiative...
What has the Alzheimer’s Prevention Initiative accomplished this past year?...
If you follow Alzheimer’s disease research at all, chances are you have heard of the families in the South American nation of Colombia...
Invite your friends over, gather loved ones, serve some good munchies, and settle in for a night of TV well worth watching...
Autosomal-dominant Alzheimer's and Huntington's disease family representatives spoke or showed videos about treatment trials...
Part 2 of Alzforum’s coverage continues with what scientists from inside and outside DIAN said about the prospect of such pre-symptomatic trials...
The charge of this meeting was to begin a dialogue toward the shared goal of offering therapeutic treatment and prevention trials to families with autosomal-dominant AD...
Could it be that a γ-secretase mutation helped give rise to communism?
Leaders of DIAN gathered to brief each other to present to some 30 pharmaceutical industry scientists the first cut of baseline data from this ongoing biomarker study...
After more than a year of rumbling to life, the Dominantly Inherited Alzheimer’s Network (DIAN) has kicked into gear and is now enrolling research participants at a healthy clip...
In a sign that prevention trials are shifting from “should do” to “will do,” academic and industry groups are getting serious about prevention trials...